Podcast Q&A: Streamlining Health Technology Assessments by Automating Literature Reviews
This podcast segment features the Q&A from DistillerSR's November 17, 2022 webinar and features a panel of experts, including Chris [...]
Health economic analysis of distributional equity impacts – a call to action
Standard cost-effectiveness analysis (CEA) does not provide the information about distributional equity impacts that decision makers need to reduce unjust differences in health by socioeconomic status, ethnicity and other aspects of social disadvantage.
Is Cost-Effectiveness Analysis Racist?
By: Michael Broder & Jesse Ortendahl Performing and using cost-effectiveness analyses is a core activity for many of us [...]
How Should a Safe and Effective COVID‑19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton
Recently, there have been encouraging commitments around the world to manufacture coronavirus disease 2019 (COVID-19) vaccines in anticipation of results from clinical studies.
Vertex Pharmaceuticals’ Cahill: One-Size-Fits-All CEA ‘Not Adequate for Every Medicine’
Vertex Pharmaceuticals VP and head of HEOR Jaime Cahill in a recent Health Affairs blog post says current cost-effectiveness evaluation [...]
Pearson: Program to Bolster Patient Involvement in Review Process
The Institute for Clinical and Economic Review's (ICER) new Patient Engagement Program is a big leap forward for the drug [...]
New Framework Introduces New Metric in Cost-Effectiveness Analysis
A recent article published in Value in Health proposes a new framework for valuing health outcomes in cost-effectiveness analyses and [...]
ISPOR Webinar to Spotlight Task Force Guidelines
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is set to host a webinar at 10:30 a.m. EST Jan. [...]
CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, [...]
Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.
Swarali Tadwalker, MPH Hardly a day goes by without a new article being published in the mainstream press [...]
Removing Bias from HEOR: Standardizing the Costs of Adverse Events
By Jim Davis What are the total costs of prescribing a particular drug? At its core, all health [...]
